Adverse events need for hospitalization and systemic immunosuppression in very elderly patients (over 80 years) treated with ipilimumab for metastatic melanoma
Vaianu Leroy(Hôpital Saint-André), Anne Pham‐Ledard(Peter MacCallum Cancer Centre), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), E. Gérard(Université de Bordeaux), A. Gey(Hôpital Saint-André), M. Beylot‐Barry, C. Mertens(Université de Bordeaux), S. Prey(Centre Hospitalier Universitaire de Bordeaux)
Cited by 22
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k